Further, the genetic deletion of SLC7A11 in various preclinical tumor models acts synergistically with immune checkpoint immunotherapeutic agents, such as anti-CTLA4, to suppress tumor growth (109). The gene discussed is SLC7A11; the disease is neoplasm.